A new scoring tool tries to predict survival when lung cancer spreads to the brain
Original title: Development and validation of a nomogram for predicting the prognosis of lung cancer patients with brain metastases harboring EGFR or ALK mutations: a multicenter retrospective study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a prediction tool built from old patient records, not a treatment you can get.
The short version
Doctors built a chart that estimates how long people with this kind of cancer may live.
What was studied. Researchers reviewed the records of 534 people whose lung cancer had spread to the brain. All of them had a change in a gene called EGFR or ALK, and their records covered 2010 to 2023.
What they found. Nine things were linked to how long people lived. They were gender, age group, smoking history, whether the cancer had spread outside the brain, where the brain tumors were and how many there were, and whether the person got radiation, targeted drugs, or chemotherapy. The team built a scoring chart from those nine things, then tested it on a separate group of 314 patients and reported that it worked well enough to sort people into risk groups.
What this means, and what it doesn't
What it could mean: This is not a new treatment. If a tool like this is used, it could help a doctor give a clearer picture of what to expect, which may help with planning care and decisions.
What it doesn't mean: This does not mean a new therapy is coming, and it is not a cure. The team looked back at records that already existed. They did not test a new treatment in people. A chart like this gives an average picture for a group, so it can be wrong for any one person. It is not part of everyday care, and it would need to hold up in other groups of patients first.
Source: PubMed, July 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.